• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Quipt Home Medical Completes Strategic Acquisition of Hart Medical Adding $60 Million in Revenue

    9/3/25 7:30:00 AM ET
    $QIPT
    Misc Health and Biotechnology Services
    Health Care
    Get the next $QIPT alert in real time by email

    CINCINNATI, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Quipt Home Medical Corp. ("Quipt" or the "Company") (NASDAQ:QIPT, TSX:QIPT), a U.S. based home medical equipment provider, focused on end-to-end respiratory care, today announced the closing of its previously announced joint venture transaction with three major health systems and two hospitals to acquire Hart Medical Equipment ("Hart"). Quipt has acquired a 60% ownership interest in Hart, with the remaining 40% interest collectively held by Henry Ford Health, McLaren Health Care, Blanchard Valley Health System, Wood County Hospital, and The Bellevue Hospital.

    Transaction Highlights:

    • Quipt has acquired a 60% ownership interest in Hart for total consideration of $17.4 million which was funded by senior credit facilities.



    • Hart generated approximately $60 million in annual revenue and $7 million in Adjusted EBITDA for the twelve months ended June 2025 and expects to generate $10+ million in annual Adjusted EBITDA over the next 6-9 months.



    • Management anticipates Hart's Adjusted EBITDA margins will align with Quipt's historical corporate averages over the next 6-9 months.



    • For reporting purposes, Quipt expects to consolidate the financial results of Hart. Accordingly, Quipt's expected annualized run-rate revenue is now in excess of $300 million. Upon successful integration of Hart over the next 6-9 months, Quipt's Adjusted EBITDA is anticipated to be in excess of $65 million. As the primary beneficiary of the joint venture it is expected that the 40% non-controlling equity interest will be reported as a separate component on the Company's Consolidated Statements of Financial Position.



    • Hart maintains longstanding strategic relationships with leading integrated health systems, including Henry Ford Health, McLaren Health Care and Blanchard Valley Health, as well as freestanding community-based hospitals, embedding the business into the hospital discharge processes of more than 19 hospitals and affiliated care facilities across its network.



    • Hart serves more than 67,000 patients monthly, providing a stable and recurring revenue stream.

    Management Commentary:

    "We are excited to officially close this milestone transaction with three major health systems and welcome Hart to the Quipt family," said Greg Crawford, CEO and Chairman of Quipt. "Hart's strong health system relationships and regional market leadership represent a powerful strategic fit. This acquisition demonstrates the scalability of our acquisition platform, while providing us with a major entry into Michigan and expanded reach across the Midwest. Looking ahead, we see a deep pipeline of additional opportunities that can be integrated onto our platform to further accelerate growth. With a stabilized revenue base, consistent Adjusted EBITDA performance, and building momentum within the business, we are confident in our ability to close the calendar year on a high note and carry strong momentum into 2026."

    "The successful closing of Hart underscores our disciplined approach to acquisitions and highlights the strength of our healthcare system-focused growth strategy," said Hardik Mehta, CFO of Quipt. "We funded this transaction with our existing credit facility, while maintaining a conservative leverage ratio. Importantly, we will look to increase the size of our senior credit facilities, which would provide us with additional flexibility to execute on our robust pipeline, while maintaining a modest long-term leverage profile consistent with our historical financial discipline. We are excited about the opportunities ahead and are well-positioned to generate consistent organic growth, while continuing to strengthen our platform through disciplined execution."

    Hart Medical current executive, Allen Hunt, stated, "As a DME provider deeply embedded in the needs of health systems, we continue to see extraordinary, untapped potential in our space. The recent wave of consolidation across key markets has made one thing clear: to remain relevant and accelerate growth in today's dynamic healthcare environment, additional scale is no longer optional, even for organizations like ours generating over $60 million annually. Recognizing this, we embarked on a rigorous search for a partner who could not only deliver the operational and technological scale we needed, but also share our commitment to serving the specialized needs of health system partners. In Quipt, we found that partner. Quipt brings more than just scale. Their patient-centered leadership, innovative mindset, and cultural alignment with our own make them an ideal match. Together, we are now positioned to seize the significant growth opportunities emerging throughout our service area."

    The Braff Group served as exclusive financial advisor for Hart.

    ABOUT QUIPT HOME MEDICAL

    The Company provides in-home monitoring and disease management services including end-to-end respiratory solutions for patients in the United States healthcare market. It seeks to continue to expand its offerings to include the management of several chronic disease states focusing on patients with heart or pulmonary disease, sleep disorders, reduced mobility, and other chronic health conditions. The primary business objective of the Company is to create shareholder value by offering a broader range of services to patients in need of in-home monitoring and chronic disease management. The Company's organic growth strategy is to increase annual revenue per patient by offering multiple services to the same patient, consolidating the patient's services, and making life easier for the patient.

    Reader Advisories

    Readers are cautioned that the financial information regarding the Hart disclosed herein is unaudited and derived as a result of the Company's due diligence, including a review of Hart's bank statements and tax returns.

    Unless otherwise specified, all dollar amounts in this press release are expressed in U.S. ‎dollars.‎

    Forward-Looking Statements

    Certain statements contained in this press release constitute "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 or "forward-looking information" as such term is ‎‎‎‎‎‎defined in applicable Canadian securities legislation (collectively, "forward-looking statements"). The words "may", "would", "could", "should", "potential", ‎‎‎‎‎‎‎"will", "seek", "intend", "plan", "anticipate", "believe", "estimate", "expect", "outlook", or the negatives thereof or variations of such words, and similar expressions ‎‎‎‎‎as ‎they relate to the Company are intended to ‎identify forward-looking statements, including: post integration financial results (revenue and Adjusted EBITDA) of Hart; management's expectations for Quipt's post-closing annualized run rate; management's expectations for post-closing Adjusted EBITDA for the joint venture and the timing of such results; the Company anticipating strong margin performance throughout the year and into 2026; the Company's expectations and timing of growth; the Company's expectations regarding the impact of the acquisition of the joint venture; opportunities to increase long-term shareholder value. All statements ‎other ‎than ‎statements of ‎‎historical fact, including those that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and may be forward-‎looking statements and may involve estimates, assumptions and uncertainties that could cause actual results or outcomes to differ materially from those expressed in the forward-looking statements. Such statements reflect the ‎Company's ‎current ‎views and ‎‎intentions with respect to future ‎events, and current information available to the ‎Company, and ‎are ‎subject to ‎‎certain risks, uncertainties and ‎assumptions, including, without limitation: the ‎Company successfully identifying, ‎‎‎negotiating and ‎completing additional acquisitions; operating and other financial metrics maintaining their ‎‎current trajectories, the Company not being impacted by any further external and unique events like the Medicare ‎‎75/25 rate cut and the Change Healthcare cybersecurity incident for the remainder of 2025; and the ‎Company not being subject to a material change to it cost structure. Many ‎factors could cause the actual ‎results, ‎‎performance or achievements that may be ‎expressed ‎or implied by such ‎forward-looking statements to ‎vary from ‎‎those described herein should one or more ‎of these ‎risks or ‎uncertainties materialize. Examples of such ‎risk ‎factors ‎include, without limitation: risks related ‎to credit, market ‎‎‎(including equity, commodity, foreign exchange ‎and interest ‎rate), ‎liquidity, operational ‎‎(including technology ‎and ‎infrastructure), reputational, insurance, ‎strategic, ‎regulatory, legal, ‎environmental, and ‎capital adequacy; the ‎‎general business and economic conditions in ‎the regions ‎in which the ‎Company operates; ‎the ability of the ‎‎Company to execute on key priorities, including the ‎successful ‎completion of ‎acquisitions, ‎business retention, and ‎‎strategic plans and to attract, develop and retain ‎key ‎executives; difficulty ‎integrating ‎newly acquired businesses; ‎‎the ability to implement business strategies and ‎‎pursue business opportunities; low ‎profit ‎market segments; ‎‎disruptions in or attacks (including cyber-attacks) on ‎‎the Company's information ‎technology, ‎internet, network ‎‎access or other voice or data communications systems or ‎‎services; the evolution of ‎various types ‎of fraud or other ‎‎criminal behavior to which the Company is exposed; the ‎‎failure of third parties to ‎comply with ‎their obligations to ‎‎the Company or its affiliates; the impact of new and ‎‎changes to, or application of, ‎current ‎laws and regulations; ‎‎decline of reimbursement rates; dependence on few ‎‎payors; possible new drug ‎discoveries; a ‎novel business ‎model; ‎dependence on key suppliers; granting of permits ‎‎and licenses in a highly ‎regulated ‎business; legal proceedings and litigation, including as it relates to the civil ‎‎investigative demand ("CID") ‎received from the Department of Justice; ‎increased competition; ‎changes in ‎foreign currency rates; the imposition of trade restrictions such as tariffs and retaliatory counter measures; increased ‎‎funding costs and market volatility due to ‎market illiquidity and ‎competition for ‎funding; the ‎availability of funds ‎‎and resources to pursue operations; ‎critical accounting ‎estimates and changes ‎to accounting ‎standards, policies, ‎‎and methods used by the Company; the Company's status as an emerging growth company and a smaller reporting company; the occurrence of ‎natural and unnatural ‎catastrophic ‎events or health epidemics or concerns; as well as those risk factors ‎discussed or ‎‎referred to ‎in the Company's disclosure ‎documents filed with ‎United States Securities and Exchange ‎Commission ‎ and ‎available at www.sec.gov, including the Company's most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q, and with ‎the securities ‎regulatory authorities in certain provinces of ‎Canada and ‎‎‎available at www.sedarplus.com. Should any ‎factor affect ‎the Company in an unexpected manner, or ‎should ‎‎‎assumptions underlying the forward-looking ‎statement prove ‎incorrect, the actual results or events may ‎differ ‎‎‎materially from the results or events predicted. ‎Any such forward-‎looking statements are expressly qualified ‎in their ‎‎‎entirety by this cautionary statement. Moreover, ‎the Company ‎does not assume responsibility for the ‎accuracy or ‎‎‎completeness of such forward-looking ‎statements. The ‎forward-looking statements included in this ‎press release are made as of the date of this press ‎release and the ‎Company undertakes no obligation to publicly ‎update or revise ‎‎‎any forward-looking statements, ‎other than as ‎required by applicable law‎.‎

    Non-GAAP Financial Measures

    This press release refers to "Adjusted EBITDA" which is a non-GAAP financial measures that does not have standardized meaning prescribed by generally accepted accounting principles in the United States. The ‎Company's presentation of this financial measure may not be comparable to similarly titled measures used by ‎other companies. This financial measure is intended to provide additional information to investors concerning ‎the Company's performance.‎

    Adjusted EBITDA is calculated as net loss, and adding back depreciation and amortization, right-of-use operating lease amortization and interest, interest expense, net, provision for income taxes, certain professional fees, including those related to the CID, the loss of private issuer status, and proxy contests and other actions of activist shareholders, stock-based compensation, acquisition-related costs, change in fair value of derivative liability – interest rate swaps, loss (gain) on foreign currency transactions, and share of loss in equity method investment.

    For further information please visit our website at www.quipthomemedical.com, or contact:

    Cole Stevens

    VP of Corporate Development

    Quipt Home Medical Corp.

    859-300-6455

    [email protected]

    Gregory Crawford

    Chief Executive Officer

    Quipt Home Medical Corp.

    859-300-6455

    [email protected]



    Get the next $QIPT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $QIPT

    DatePrice TargetRatingAnalyst
    5/14/2025$1.70Buy → Hold
    Canaccord Genuity
    5/17/2024Mkt Perform → Underperform
    Raymond James
    2/16/2024Outperform → Mkt Perform
    Raymond James
    6/14/2023$11.00Buy
    Canaccord Genuity
    10/20/2021$7.50Buy
    The Benchmark Company
    10/20/2021$7.50Buy
    Benchmark
    More analyst ratings

    $QIPT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Quipt Home Medical downgraded by Canaccord Genuity with a new price target

    Canaccord Genuity downgraded Quipt Home Medical from Buy to Hold and set a new price target of $1.70

    5/14/25 8:58:24 AM ET
    $QIPT
    Misc Health and Biotechnology Services
    Health Care

    Quipt Home Medical downgraded by Raymond James

    Raymond James downgraded Quipt Home Medical from Mkt Perform to Underperform

    5/17/24 7:45:25 AM ET
    $QIPT
    Misc Health and Biotechnology Services
    Health Care

    Quipt Home Medical downgraded by Raymond James

    Raymond James downgraded Quipt Home Medical from Outperform to Mkt Perform

    2/16/24 8:29:00 AM ET
    $QIPT
    Misc Health and Biotechnology Services
    Health Care

    $QIPT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Concerned Shareholder Bradley L. Radoff Urges Quipt Home Medical's Board of Directors to Pursue a Value-Maximizing Sale

    Questions Independent Director Mark Greenberg for His Role in Supporting Substantial Dilution of Shareholders and Rebuffing Inbound Interest Intends to Vote Against Every Incumbent Director at 2026 Annual Meeting if the Board Continues to Put Shareholder Value at Risk Bradley L. Radoff, who collectively with his affiliates owns approximately 4.9% of the outstanding common shares of Quipt Home Medical Corp. (NYSE:QIPT) ("Quipt" or the "Company"), today issued the following statement regarding the manner in which the Company's Board of Directors (the "Board") has failed to capitalize on apparent acquirer interest: "The Board has spent years destroying its credibility by presiding over poor

    12/5/25 4:00:00 PM ET
    $QIPT
    Misc Health and Biotechnology Services
    Health Care

    Lakeview Urges Quipt's Board to Initiate a Legitimate Review of All Strategic Options Including a Sale, Inclusive of a Credible Bidder's $3.10 All-Cash Offer

    Board Should Run a Real Review Process That is Focused on Building – Not Chilling – Acquirer Interest Lakeview Opportunity Fund, LLC (together with its affiliates, "we" or "Lakeview Investment Group"), a nearly 5% owner, and top 5 shareholder of Quipt Home Medical Corp. ("Quipt" or the "Company") (NASDAQ:QIPT, TSX:QIPT), today expressed its belief that the Company's Board of Directors (the "Board") has undermined the best interests of shareholders by failing to engage in good faith with a credible bidder as part of a transparent and viable strategic review. Rather than open a constructive dialogue with a real bidder and start exploring all avenues to maximize value, the Board has put shar

    10/22/25 12:10:00 PM ET
    $QIPT
    Misc Health and Biotechnology Services
    Health Care

    Forager's 120% Premium for Quipt Would Set M&A Benchmark; Board's Inaction Erodes Shareholder IRR

    BIRMINGHAM, Ala., Sept. 10, 2025 (GLOBE NEWSWIRE) -- Forager Capital Management ("Forager"), one of the largest shareholders of Quipt Home Medical Corp. ("Quipt") (NASDAQ:QIPT, TSX:QIPT), with beneficial ownership of 9.7% of the outstanding shares, issued the following statement: "On May 17, 2025 — nearly sixteen weeks ago — Forager submitted an offer to acquire Quipt for $3.10 per share in cash (the "May Offer"). Had Quipt's Board constructively engaged, the transaction could have been completed by now under the timeline outlined in the May Offer. Shareholders would have locked in a 120% return in under six months — a gain that could have already been redeployed into new opport

    9/10/25 8:30:00 AM ET
    $QIPT
    Misc Health and Biotechnology Services
    Health Care

    $QIPT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Wessel Brian Joseph was granted 183,135 shares, increasing direct ownership by 1,297% to 197,260 units (SEC Form 4)

    4 - Quipt Home Medical Corp. (0001540013) (Issuer)

    3/25/25 7:37:03 AM ET
    $QIPT
    Misc Health and Biotechnology Services
    Health Care

    Chief Accounting Officer Roehrig Thomas was granted 110,000 shares, increasing direct ownership by 175% to 173,000 units (SEC Form 4)

    4 - Quipt Home Medical Corp. (0001540013) (Issuer)

    3/25/25 7:36:22 AM ET
    $QIPT
    Misc Health and Biotechnology Services
    Health Care

    Chief Compliance Officer Miles Mark Alan was granted 110,000 shares (SEC Form 4)

    4 - Quipt Home Medical Corp. (0001540013) (Issuer)

    3/25/25 7:35:41 AM ET
    $QIPT
    Misc Health and Biotechnology Services
    Health Care

    $QIPT
    SEC Filings

    View All

    Quipt Home Medical Corp. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Quipt Home Medical Corp. (0001540013) (Filer)

    8/27/25 8:15:08 AM ET
    $QIPT
    Misc Health and Biotechnology Services
    Health Care

    Amendment: SEC Form SCHEDULE 13D/A filed by Quipt Home Medical Corp.

    SCHEDULE 13D/A - Quipt Home Medical Corp. (0001540013) (Subject)

    8/25/25 8:31:47 AM ET
    $QIPT
    Misc Health and Biotechnology Services
    Health Care

    Quipt Home Medical Corp. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits

    8-K - Quipt Home Medical Corp. (0001540013) (Filer)

    8/12/25 5:00:58 PM ET
    $QIPT
    Misc Health and Biotechnology Services
    Health Care

    $QIPT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Exec VP Operations Gamble Patrick Dennis bought $41,634 worth of shares (17,000 units at $2.45), increasing direct ownership by 74% to 40,057 units (SEC Form 4)

    4 - Quipt Home Medical Corp. (0001540013) (Issuer)

    12/30/24 4:05:11 PM ET
    $QIPT
    Misc Health and Biotechnology Services
    Health Care

    $QIPT
    Leadership Updates

    Live Leadership Updates

    View All

    Quipt Home Medical Unveils Strategic Priorities for 2025 to Enhance Shareholder Value and Announces Voting Results from its Annual General Meeting

    CINCINNATI, March 24, 2025 (GLOBE NEWSWIRE) -- Quipt Home Medical Corp. ("Quipt" or the "Company") (NASDAQ:QIPT, TSX:QIPT)‎, a U.S. based home medical equipment provider, focused on end-to-end respiratory care, is pleased to announce its strategic priorities for calendar 2025 and the voting results from its annual general meeting of shareholders held on March 17, 2025 (the "Meeting") in Sarasota, Florida. The total number of shares represented in person or by proxy at the Meeting was 31,400,043, representing 72.87% of the total issued and outstanding shares in the capital of the Company. As it relates to its strategic priorities for 2025, the Company remains committed to returning to hist

    3/24/25 7:30:00 AM ET
    $QIPT
    Misc Health and Biotechnology Services
    Health Care

    Quipt Home Medical Announces Voting Results from Its Annual General and Special Meeting of Shareholders

    CINCINNATI, March 28, 2024 (GLOBE NEWSWIRE) -- Quipt Home Medical Corp. (the "Company") (NASDAQ:QIPT) (TSX:QIPT)‎, a U.S. based home medical equipment provider, focused on end-to-end respiratory care, today announced the voting results from its annual general and special meeting of shareholders held on March 27, 2024 (the "Meeting") in Wilder, Kentucky. The total number of shares represented in person or by proxy at the Meeting was 25,432,699, representing 60.4% of the total issued and outstanding shares in the capital of the Company. Election of Directors The four candidates nominated for election to the Company's Board of Directors (the "Board") and listed in the Company's manageme

    3/28/24 7:30:00 AM ET
    $QIPT
    Misc Health and Biotechnology Services
    Health Care

    Quipt Home Medical Announces New Independent Board Member

    CINCINNATI, Feb. 03, 2022 (GLOBE NEWSWIRE) -- Quipt Home Medical Corp. ("Quipt" or the "Company") (NASDAQ:QIPT, TSXV:QIPT), a U.S. based leader in the home medical equipment industry, focused on end-to-end respiratory care, announced today that Mr. Brian J. Wessel has joined the Board of Directors of the Company as an Independent Director and Chair of the Audit Committee. Mr. Wessel is a senior business executive with over 34 years of global client service, operational and financial expertise. As a former senior partner at Ernst & Young ("EY"), Mr. Wessel provided audit and advisory services to public, private, and private-equity-owned companies across multiple industry sectors. Additio

    2/3/22 7:30:00 AM ET
    $QIPT
    Misc Health and Biotechnology Services
    Health Care

    $QIPT
    Financials

    Live finance-specific insights

    View All

    Quipt Home Medical Reports Improved Fiscal Third Quarter 2025 Results

    Posts Positive Organic Growth and Adjusted EBITDA‎1 of 23.5% of Revenue CINCINNATI, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Quipt Home Medical Corp. ("Quipt" or the "Company") (NASDAQ:QIPT, TSX:QIPT), a U.S. based home medical equipment provider, focused on end-to-end respiratory care, today announced its fiscal third quarter 2025 financial results and operational highlights. These results pertain to the three and nine months ended June 30, 2025, and are reported in United States dollars. Conference Call Quipt will host its Earnings Conference Call on Tuesday, August 12, 2025 at 10:00 a.m. (ET). Interested parties may participate in the call by dialing 1 (833) 752-3722 or 1 (647) 846-85

    8/11/25 5:00:00 PM ET
    $QIPT
    Misc Health and Biotechnology Services
    Health Care

    Quipt Home Medical Corp. to Announce Fiscal Third Quarter 2025 Financial Results on August 11, 2025

    CINCINNATI, July 29, 2025 (GLOBE NEWSWIRE) -- Quipt Home Medical Corp. (the "Company") (NASDAQ:QIPT) (TSX:QIPT), a U.S. based home medical equipment provider, focused on end-to-end respiratory care, will announce its fiscal Third quarter 2025 financial results on Monday, August 11, 2025, after market close. Gregory Crawford, Chief Executive Officer, and Hardik Mehta, Chief Financial Officer, will host a conference call for the investment community on Tuesday, August 12, 2025, at 10:00 a.m. (ET). The call-in numbers for participants are:  Canada/US Toll Free:1 (833) 752 3722 International:1 (647) 846 8549    A live webcast of the call will be accessible via the investor

    7/29/25 7:30:00 AM ET
    $QIPT
    Misc Health and Biotechnology Services
    Health Care

    Quipt Home Medical Acquires Healthcare System Owned Medical Equipment Provider with $6.6 Million in Revenue, and Signs Preferred Provider Agreement Covering 20 Hospitals Across 4 States

    CINCINNATI, July 07, 2025 (GLOBE NEWSWIRE) -- Quipt Home Medical Corp. ("Quipt" or the "Company") (NASDAQ:QIPT, TSX:QIPT), a U.S. based home medical equipment provider, focused on end-to-end respiratory care, today announced it has acquired a full-service durable medical equipment ("DME") provider, which is wholly owned by Ballad Health (the "Acquiree"). Ballad Health is a prominent integrated health system comprised of 20 hospitals, post-acute care and behavioral health services, and a large multi-specialty group physician practice. Ballad Health serves 29 counties of the Appalachian Highlands in Northeast Tennessee, Southwest Virginia, Northwest North Carolina and Southeast Kentucky. The

    7/7/25 7:30:00 AM ET
    $QIPT
    Misc Health and Biotechnology Services
    Health Care

    $QIPT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D filed by Quipt Home Medical Corp.

    SC 13D - Quipt Home Medical Corp. (0001540013) (Subject)

    12/11/24 4:07:36 PM ET
    $QIPT
    Misc Health and Biotechnology Services
    Health Care

    Amendment: SEC Form SC 13G/A filed by Quipt Home Medical Corp.

    SC 13G/A - Quipt Home Medical Corp. (0001540013) (Subject)

    12/11/24 4:06:42 PM ET
    $QIPT
    Misc Health and Biotechnology Services
    Health Care

    SEC Form SC 13G filed by Quipt Home Medical Corp.

    SC 13G - Quipt Home Medical Corp. (0001540013) (Subject)

    12/11/24 4:06:09 PM ET
    $QIPT
    Misc Health and Biotechnology Services
    Health Care